Related Experiment Videos
What is the optimal therapy for childhood AML?
David M Loeb1, Robert J Arceci
1Johns Hopkins Oncology Center, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21231, USA.
Oncology (Williston Park, N.Y.)
|August 31, 2002
Summary
Intensive therapy improves outcomes for pediatric acute myelogenous leukemia (AML) patients, but cure rates remain around 50%. Future advances in pediatric AML treatment may come from alternative strategies beyond intensified chemotherapy.
Area of Science:
- Pediatric Oncology
- Hematology
- Leukemia Research
Background:
- Intensive therapy has significantly improved outcomes for pediatric acute myelogenous leukemia (AML).
- Despite advances like high-intensity chemotherapy and bone marrow transplantation, cure rates for pediatric AML remain approximately 50%.
- Further increases in chemotherapy intensity are unlikely to yield substantial improvements.
Purpose of the Study:
- To explore alternative therapeutic strategies for improving cure rates in pediatric acute myelogenous leukemia (AML).
- To identify novel approaches beyond conventional intensive chemotherapy for treating pediatric AML.
Main Methods:
- Review of existing studies on intensive therapy for pediatric AML.
- Exploration of alternative treatment modalities including risk-directed therapy, differentiation therapy, and immunotherapy.
Main Results:
- Intensive therapy has demonstrated dramatic improvements in pediatric AML outcomes.
- Current intensive chemotherapy and bone marrow transplantation achieve cure rates of about 50% in children with AML.
Conclusions:
- Future progress in pediatric AML treatment necessitates exploring alternative strategies.
- Promising alternative approaches include risk-directed therapy, differentiation agents (ATRA, arsenic trioxide, azacytidine), and immunotherapy (monoclonal antibodies, vaccines, cytokines).